Approved cancer drug may reduce kidney damage linked to nail-patella syndrome

Researchers led by Dr. Ralph Witzgall, a professor at the Chair of Molecular and Cellular Anatomy at the University of Regensburg, have deciphered a key disease mechanism underlying the hereditary kidney disorder nail-patella syndrome and identified a potential therapeutic strategy. Their findings demonstrate that an already approved drug can significantly reduce disease-causing changes. The study, which also involved researchers from the Technical University of Munich (TUM), was recently published in the journal Nature Communications.

≈